Emergent Biosolutions (EBS) said Wednesday it entered into a new credit agreement for an asset-based revolving loan facility, effective Sept. 30, with Wells Fargo Bank as administrative agent.

The credit agreement provides for revolving loan commitments of up to $100 million with a maturity date of 2029, the company said.

As of Sept. 30, Emergent said it had a cash balance of $150 million and undrawn access to $100 million under the loan facility.

Price: 8.48, Change: +0.01, Percent Change: +0.12